SF433 • 2026

A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

Healthcare

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: WAHLS
Last action: 2025-03-03
Official status: Subcommittee: Klimesh, Costello, and Wahls. S.J. 393 .
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

What This Bill Does

A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2025-03-03 Iowa Legislature
Subcommittee: Klimesh, Costello, and Wahls. S.J. 393 .
2025-02-25 Iowa Legislature
Introduced, referred to Health and Human Services. S.J. 353 .

Official Summary Text

A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

Current Bill Text

Read the full stored bill text

Senate

File

433

-

Introduced

SENATE

FILE

433

BY

WAHLS

A

BILL

FOR

An

Act

relating

to

direct

acting

antiviral

medications,

1

including

prior

authorization

requirements,

and

the

Iowa

2

medical

assistance

drug

utilization

review

commission.

3

BE

IT

ENACTED

BY

THE

GENERAL

ASSEMBLY

OF

THE

STATE

OF

IOWA:

4

TLSB

1440XS

(4)

91

lh/ko

S.F.

433

Section

1.

DIRECT

ACTING

ANTIVIRAL

MEDICATION

——

MEDICAID

1

PRIOR

AUTHORIZATION.

Notwithstanding

section

249A.20A,

2

subsection

4,

the

department

of

health

and

human

services

shall

3

not

require

prior

authorization

for

any

direct

acting

antiviral

4

medications

used

to

treat

hepatitis

C

that

are

on

the

preferred

5

drug

list.

6

Sec.

2.

IOWA

MEDICAL

ASSISTANCE

DRUG

UTILIZATION

REVIEW

7

COMMISSION

——

VOSEVI

REVIEW.

The

Iowa

medical

assistance

drug

8

utilization

review

commission

created

under

section

249A.24

9

shall,

by

July

1,

2026,

review

the

prescription

drug

vosevi

for

10

placement

on

the

preferred

drug

formulary

pursuant

to

42

U.S.C.

11

§1396r-8

as

a

preferred

direct

acting

antiviral

for

treatment

12

of

hepatitis

C.

13

EXPLANATION

14

The

inclusion

of

this

explanation

does

not

constitute

agreement

with

15

the

explanation’s

substance

by

the

members

of

the

general

assembly.

16

This

bill

relates

to

direct

acting

antivirals,

including

17

prior

authorization

requirements,

and

the

Iowa

medical

18

assistance

drug

utilization

review

commission

(commission).

19

The

bill

prohibits

the

department

of

health

and

human

20

services

from

requiring

prior

authorization

for

direct

acting

21

antiviral

medications

used

to

treat

hepatitis

C

that

are

on

the

22

preferred

drug

list

for

the

medical

assistance

program.

23

The

bill

requires

the

commission

to

review,

by

July

1,

2026,

24

the

prescription

drug

vosevi

for

placement

on

the

preferred

25

drug

list

pursuant

to

42

U.S.C.

§1396r-8

as

a

preferred

direct

26

acting

antiviral

for

treatment

of

hepatitis

C.

27

-1-

LSB

1440XS

(4)

91

lh/ko

1/

1